目的 调查2017-2018年中国医科大学附属第一医院氟比洛芬酯的应用情况并对用药合理性进行评价。方法 利用中国医科大学附属第一医院的电子病例管理系统，调取2017年1~6月、2018年1~6月应用氟比洛芬酯注射液的全部住院病例，统计药品使用数量及科室排名，并对抽样调查的843例病例从适应症适宜性、药品遴选适宜性、用法用量适宜性、疗程适宜性及联合用药与相互作用适宜性几个方面进行合理性评价。结果 2018年氟比洛芬酯的消耗数量较2017年同期下降17%；843例病例中不合理率为61.0%，其中药品遴选不适宜占32.3%，用法用量不适宜占17.1%，用药疗程不适宜占53.0%，联合用药或相互作用不适宜占1.9%。结论 中国医科大学附属第一医院氟比洛芬酯的临床应用广泛，不合理现象较为严重，应加强管理，提高临床合理用药意识。

Objective To investigate the application of flurbiprofen axetil in the First Hospital of China Medical University from 2017 to 2018, and to evaluate the rationality of the medication use. Methods By using the electronic case management system of the First Hospital of China Medical University, all the inpatients who used Flurbiprofen Axetil Injection in January to June 2017 and January to June 2018 were selected, and the number of drugs used and the ranking of departments were counted. The 843 cases in the sampling survey were further studied from the aspects of suitability for indications, suitability for drug selection, suitability for usage and dosage, suitability for treatment course, and suitability for combination and interaction. Results The consumption of flurbiprofen axetil in 2018 decreased by 17% compared with the same period in 2017. In 843 cases, the unreasonable rate was 61.0%, in which 32.3% were unsuitable for drug selection, 17.1% were unsuitable for usage and dosage, 53.0% were unsuitable for treatment course, and 1.9% were unsuitable for combination or interaction. Conclusion Flurbiprofen axetil is widely used in clinic in the First Hospital of China Medical University, and its unreasonable phenomenon is serious. Medical institutions should strengthen the management and improve the consciousness of rational use of drugs in clinical practice.

R969.3